title: Hepatitis B reactivation in a hepatitis B surface antigen-negative patient after allogeneic bone marrow transplant: successful treatment with lamivudine and seroconversion.
abstract: Hepatitis B reactivation in hepatitis B surface antigen (HBsAg)-negative and anti-HBsAg antibodies-positive patients is an infrequent complication of chemotherapy, usually with fatal evolution. Here we report an HBsAg-negative patient with a myelodysplastic syndrome, who developed hepatitis B reactivation after chemotherapy and evolved favorably after lamivudine treatment, allowing seroconversion.
authors.affiliation: Departamento de Microbiología, Hospital Universitario, 37007 Salamanca, Spain.
authors.forename: Rosa
authors.initials: R
authors.lastname: Pérez-Grande
authors.forename: Nieves
authors.initials: N
authors.lastname: Gutiérrez-Zufiaurre
authors.forename: Santiago
authors.initials: S
authors.lastname: Muñoz-Criado
authors.forename: Ana M
authors.initials: AM
authors.lastname: Blázquez de Castro
authors.forename: Lourdes
authors.initials: L
authors.lastname: Vázquez López
authors.forename: Francisco
authors.initials: F
authors.lastname: González San Martín
authors.forename: Jose Angel
authors.initials: JA
authors.lastname: García Rodríguez
authors.forename: Juan Luis
authors.initials: JL
authors.lastname: Muñoz Bellido
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D005260:Female; D006509:Hepatitis B / Q000175:diagnosis* / Q000188:drug therapy*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D019259:Lamivudine / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D007166:Immunosuppressive Agents; D019259:Lamivudine